Clinical trial registry record

A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 26, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07363057
Last registry update
January 26, 2026
Status
Recruiting
Phase
Phase 2
Sponsor
GI Innovation, Inc.
Enrollment
15
Countries
Australia
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · SINGLE
Evidence population
Human clinical study registration
Participants
15
Population
ALL · 18 Years to 80 Years
Duration
2026-01-01 to 2026-10-01
Intervention
GI-102 in combination with GIB-7; Placebo
Comparator
Part A; Part B Arm 1; Part B Arm 2
Outcomes measured
Change in Baseline values in immune response (NK cells) before and after GI-102 and GIB-7 combination treatment — From…; Change in Baseline values in immune response (CD8+ T cells) before and after GI-102 and GIB-7 combination treatment — F…; Frequency of Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) of the combination of GI-102 a…; Number of participants with various adverse events and abnormal lab data — From Day 1 until Week 10 visit; Change in Baseline values in sleep quality before and after GI-102 and GIB-7 combination treatment — From Day 1 until W…; Change in Baseline values in quality of life before and after GI-102 and GIB-7 combination treatment — From Day 1 until…; Change in Baseline values in muscle function (hand grip strength) before and after GI-102 and GIB-7 combination treatme…; Change in Baseline values in muscle function (6 minute walk test) before and after GI-102 and GIB-7 combination treatme…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Cancer and ageing · 100%Title contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.

cancer and aging
Read the original source →Export JSON